E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
patients affected by advanced or metastatic malignant pleural mesothelioma previously treated with no more than one systemic therapeutic |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 6.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10035605 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Antitumor activity defined as progression free survival (PFS) |
|
E.2.2 | Secondary objectives of the trial |
Tumor Growth Control Rate (TGCR) according to RECIST criteria;Overall survival (OS); Circulating Endothelial Cells (CECs);Experimental Imaging Study (DCE-MRI);Safety |
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
ユPatients >=18 years affected by malignant pleural mesothelioma previously treated with no more than one systemic therapeutic regimen ユHistologically or cytological confirmed malignant pleural mesothelioma of any of the following subtype: epithelial, sarcomatous, mixed ユPrior intrapleural cytotoxic agents including bleomycin not considered systemic chemotherapy ユECOG Performance status 0 ヨ 2 ユAdequate baseline bone marrow, hepatic and renal function, defined as follows: -Neutrophils > 1.5 x 10^9/L and platelets > 100 x 10^9/L -Bilirubin < 1.5 x ULN -AST and/or ALT < 2.5 x ULN in absence of liver metastasis -AST and/or ALT < 5 x ULN in presence of liver metastasis -Serum creatinine < 1.5 x ULN ユAbsence of any conditions in which hypervoleamia and its consequences (e.g. increased stroke volume, elevated blood pressure) or haemodilution could represent a risk for the patient (take as reference モTechnical data sheet human albuminヤ specifically used in Pharmacy Department for NGR-hTNF dilution) ユPatients may have had prior therapy providing the following conditions are met: -Chemotherapy and radiotherapy: wash-out period of 28 days -Surgery: wash-out period of 14 days ユNormal cardiac function and absence of uncontrolled hypertension ユPatients must give written informed consent to participate in the study |
|
E.4 | Principal exclusion criteria |
ユConcurrent anticancer therapy ユPatients may not receive any other investigational agents while on study ユClinical signs of CNS involvement ユPatients with active or uncontrolled systemic disease/infections or with serious illness or medical conditions, which is incompatible with the protocol ユKnown hypersensitivity/allergic reaction to human albumin preparations or to any of the excipients ユAny psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol ユPregnancy or lactation. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Antitumor activity defined as progression free survival (PFS) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 8 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 8 |